True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis

American Heart Journal

Volumn 188, Issue , 2017, Pages 99-108

  Vukadinović, Davor ^a   Lavall, Daniel ^a   Vukadinović, Aleksandra Nikolovska ^a   Pitt, Bertram ^b   Wagenpfeil, Stefan ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ARTICLE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL (TOPIC); GLOBAL HEALTH; RISK FACTOR;

CONTROLLED CLINICAL TRIALS AS TOPIC; GLOBAL HEALTH; HEART FAILURE; HUMANS; HYPERKALEMIA; INCIDENCE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RISK FACTORS;

EID: 85016571674     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.03.011     Document Type: Article

References (45)

1. 1. Weber, K.T., Aldosterone in congestive heart failure. N Engl J Med 345:23 (2001), 1689–1697.
2. 2. Lavall, D., Selzer, C., Schuster, P., et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 289:10 (2014), 6656–6668.
3. 3. Nguyen Dinh Cat, A., Jaisser, F., Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens 21:2 (2012), 147–156.
4. 4. Zannad, F., McMurray, J.J., Krum, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:1 (2011), 11–21.
5. 5. Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:10 (1999), 709–717.
6. 6. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:27 (2016), 2129–2200.
7. 7. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:16 (2013), e147–e239.
8. 8. Pitt, B., Remme, W., Zannad, F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:14 (2003), 1309–1321.
9. 9. Weir, M.R., Rolfe, M., Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 5:3 (2010), 531–548.
10. 10. Krogager, M.L., Torp-Pedersen, C., Mortensen, R.N., et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J, 2016.
11. 11. Albert, N.M., Yancy, C.W., Liang, L., et al. Use of aldosterone antagonists in heart failure. JAMA 302:15 (2009), 1658–1665.
12. 12. Rassi, A.N., Cavender, M.A., Fonarow, G.C., et al. Temporal trends and predictors in the use of aldosterone antagonists post–acute myocardial infarction. J Am Coll Cardiol 61:1 (2013), 35–40.
13. 13. Fonarow, G.C., Yancy, C.W., Albert, N.M., et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail 1:2 (2008), 98–106.
14. 14. Nieminen, M.S., Brutsaert, D., Dickstein, K., et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27:22 (2006), 2725–2736.
15. 15. Lopez-de-Sa, E., Martinez, A., Anguita, M., et al. Aldosterone receptor antagonist use after myocardial infarction. Data from the REICIAM registry. Rev Esp Cardiol 64:11 (2011), 981–987.
16. 16. von Scheidt, W., Zugck, C., Pauschinger, M., et al. Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry. Clin Res Cardiol 103:12 (2014), 1006–1014.
17. 17. Tebbe, U., Tschöpe, C., Wirtz, J.H., et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol 103:8 (2014), 665–673.
18. 18. Rossignol, P., Girerd, N., Bakris, G., et al. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail, 2016 [Epub ahead of print Nov 20].
19. 19. Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:4 (2009), 264–269 [W64].
20. 20. Chin, K.L., Skiba, M., Tonkin, A., et al. The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. Heart Fail Rev 21:6 (2016), 675–697.
21. 21. Barron, A.J., Zaman, N., Cole, G.D., et al. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 168:4 (2013), 3572–3579.
22. 22. Rockhill, B., Weinberg, C.R., Newman, B., Population attributable fraction estimation for established breast cancer risk factors: considering the issues of high prevalence and unmodifiability. Am J Epidemiol 147:9 (1998), 826–833.
23. 23. Wang, T.Y., Vora, A.N., Peng, S.A., et al. Effectiveness and safety of aldosterone antagonist therapy use among older patients with reduced ejection fraction after acute myocardial infarction. J Am Heart Assoc, 5(1), 2016.
24. 24. Hernandez, A.F., Mi, X., Hammill, B.G., et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 308:20 (2012), 2097–2107.
25. 25. Vardeny, O., Claggett, B., Anand, I., et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7:4 (2014), 573–579.
26. 26. Montalescot, G., Pitt, B., Lopez de Sa, E., et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J 35:34 (2014), 2295–2302.
27. 27. Edelmann, F., Wachter, R., Schmidt, A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309:8 (2013), 781–791.
28. 28. Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370:15 (2014), 1383–1392.
29. 29. Juurlink, D.N., Mamdani, M.M., Lee, D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:6 (2004), 543–551.
30. 30. Hirt, M.N., Muttardi, A., Helms, T.M., et al. General practitioners’ adherence to chronic heart failure guidelines regarding medication: the GP-HF study. Clin Res Cardiol 105:5 (2016), 441–450.
31. 31. Maggioni, A.P., Anker, S.D., Dahlstrom, U., et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15:10 (2013), 1173–1184.
32. 32. Rossignol, P., Zannad, F., Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. Circulation 131:1 (2015), 7–10.
33. 33. Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131:1 (2015), 34–42.
34. 34. Sica, D.A., Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10:1 (2005), 23–29.
35. 35. Pitt, B., Zannad, F., Eplerenone: is it time to add this drug to current heart failure therapy?. Ther Adv Chronic Dis 3:1 (2012), 5–9.
36. 36. Bowling, C.B., Pitt, B., Ahmed, M.I., et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 3:2 (2010), 253–260.
37. 37. Damman, K., Valente, M.A., Voors, A.A., et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:7 (2014), 455–469.
38. 38. Pitt, B., Bakris, G., Ruilope, L.M., et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118:16 (2008), 1643–1650.
39. 39. Rossignol, P., Dobre, D., McMurray, J.J., et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7:1 (2014), 51–58.
40. 40. Palmer, B.F., Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351:6 (2004), 585–592.
41. 41. Carraro, P., Servidio, G., Plebani, M., Hemolyzed specimens: a reason for rejection or a clinical challenge?. Clin Chem 46:2 (2000), 306–307.
42. 42. Sevastos, N., Theodossiades, G., Archimandritis, A.J., Pseudohyperkalemia in serum: a new insight into an old phenomenon. Clin Med Res 6:1 (2008), 30–32.
43. 43. Cooper, L.B., Hammill, B.G., Peterson, E.D., et al. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA 314:18 (2015), 1973–1975.
44. 44. Shah, K.B., Rao, K., Sawyer, R., et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 46:5 (2005), 845–849.
45. 45. Udelson, J.E., Feldman, A.M., Greenberg, B., et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 3:3 (2010), 347–353.